Replies to post #181021 on Biotech Values

[Double_Bagel]

Until now, it wasn't a certainty that NVS would decide to advance the EDP-239 program.

Excellent! I see this from your 6/22/13 post. Thanks again for all you do here in the BV board. I appreciate it greatly :-)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89280314

On EDP-239, ENTA is theoretically eligible to receive $395M in pre-commercial milestones and $160M in commercial milestones from NVS, as well as a double-digit royalty on worldwide sales. (ENTA already received $34M up-front and $11M in clinical milestones from NVS.) NVS funds all development and commercialization expenses worldwide. I used the word theoretically at the beginning of this paragraph because the EDP-239 program appears to be in the slow lane; I’m not convinced it will amount to anything since NVS appears to have pulled away from the HCV arena.